Hardly a week seems to go by without something positive emerging from either Eli Lilly and Company (LLY) or its other major competitor, Novo Nordisk (NVO), on the prospects of the GLP-1 weight loss drugs. The ongoing week has again held true to this emerging bullish regimen, with Eli Lilly garnering significant positive developments in the battle to counter Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops most often due to metabolic disorders, including obesity and diabetes. This accumulation […]
Read full article at https://wccftech.com/eli-lilly-and-company-tirzepatide-glp-1-agonist-is-found-to-reduce-damage-from-fatty-liver-disease/
WccftechContinue reading/original-link]
